In a small study, intravenous mistletoe extract showed promise as a cancer therapy.
While the phase 1 trial was meant to evaluate the drug’s safety, researchers also documented improved quality of life and some disease control among study participants with advanced and treatment-resistant cancers.
Mistletoe extract has been widely used to support cancer therapy and improve quality of life, but there has been a lack of clinical trials and data to support its use. Researchers at the Johns Hopkins Kimmel Cancer Center completed what is believed to be the first phase 1 trial of intravenous Helixor M in the United States, aimed at determining dosing for subsequent clinical trials and to evaluate safety….